10x Genomics EBITDA
¿Qué es el EBITDA de 10x Genomics?
El EBITDA de 10x Genomics, Inc. es -$117.15
¿Cuál es la definición de EBITDA?
El EBITDA es la ganancia de una compañía antes de intereses, impuestos, depreciación y amortización y es una medida contable calculada usando las ganancias netas de la compañía, antes de que se resten los gastos de interés, los impuestos, la depreciación y la amortización, como un proxy de la rentabilidad operativa actual de la compañía.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA de compañías en Sector Health Care en NASDAQ en comparadas con 10x Genomics
¿Qué hace 10x Genomics?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Empresas con ebitda similar a 10x Genomics
- B. Riley Inc tiene EBITDA de -$118.65
- B. Riley Inc tiene EBITDA de -$118.65
- Freeline Therapeutics plc tiene EBITDA de -$118.33
- TFG International tiene EBITDA de -HKD$118.24
- New Century Healthcare Co tiene EBITDA de -¥118.18
- Rudra Global Infra Products tiene EBITDA de -₨117.27
- 10x Genomics tiene EBITDA de -$117.15
- Radaan Mediaworks India tiene EBITDA de -₨117.09
- Palash Securities tiene EBITDA de -₨116.97
- Progenity tiene EBITDA de -$116.40
- Syros Pharmaceuticals tiene EBITDA de -$116.00
- China Yurun Food tiene EBITDA de -HKD$114.97
- Ashok Alco-Chem tiene EBITDA de -₨114.91